| Rank |
Status |
Study |
| 1 |
Unknown †
|
Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.
| Condition: |
Chronic Stable Angina |
| Interventions: |
Drug: Nicorandil; Drug: Atenolol |
| Outcome Measures: |
SPECT Tc99m- Tetrofosmin (MYOVIEW); Exercise ECG Testing - Bruce protocol |
|
| 2 |
Recruiting
|
Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol
| Condition: |
Marfan Syndrome |
| Interventions: |
Drug: Aliskiren; Drug: Atenolol |
| Outcome Measures: |
Central aortic PWV(pulsed wave velocity); Central aortic distensibility by MRI at week 24 |
|
| 3 |
Recruiting
|
A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function
| Condition: |
Hypertension |
| Interventions: |
Drug: Nebivolol; Drug: Atenolol; Drug: placebo |
| Outcome Measures: |
Comparing effects of nebivolol against Atenolol and placebo on endothelial function; Evaluate effects of nebivolol as compared to Atenolol and placebo |
|
| 4 |
Recruiting
|
Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation
| Condition: |
Atrial Fibrillation |
| Intervention: |
Drug: Atenolol |
| Outcome Measure: |
Ventricular rate response during exercise. |
|
| 5 |
Recruiting
|
Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients
| Condition: |
Hypertension |
| Interventions: |
Drug: Fimasartan; Drug: Atenolol |
| Outcome Measures: |
The difference of sitting Systolic Blood Pressure(SiSBP) between at the peak compared to at resting; The difference of sitting Diastolic Blood Pressure(SiDBP) at the peak compared to at resting; The difference of sitting Systolic Blood Pressure(SiSBP) at each exercising stage compared to at resting; The difference of sitting Systolic Blood Pressure(SiSBP) among at resting, each exercising stage and recovery |
|
| 6 |
Recruiting
|
Hemodynamic Changes of Patients Receiving Atenolol/Bisoprolol
| Conditions: |
Hypertension; Metabolic Syndrome |
| Interventions: |
Drug: Atenolol; Drug: Bisoprolol |
| Outcome Measures: |
central blood pressure; peripheral resistance; cardiac index; pulse wave velocity |
|
| 7 |
Recruiting
|
Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study)
| Condition: |
Cardiac Disease |
| Interventions: |
Drug: Atenolol; Drug: Telmisartan |
| Outcome Measures: |
Change from baseline in ascending aorta size, as evaluated by MRI; Rate of change in ascending aorta size evaluated by transthoracic echocardiography (TEE). |
|
| 8 |
Unknown †
|
Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes
| Condition: |
Diabetes Mellitus, Type 2 |
| Intervention: |
Drug: Atenolol |
| Outcome Measures: |
Change in diastolic function (annular tissue velocity [Em]); Change in free fatty acid kinetics; Change in insulin sensitivity, glucose effectiveness, glucose, insulin, high-density lipoprotein (HDL), or triglycerides |
|
| 9 |
Unknown †
|
A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome
| Condition: |
Marfan Syndrome |
| Interventions: |
Drug: Losartan and Atenolol or Propranolol; Drug: Atenolol or Propranolol |
| Outcome Measure: |
Echocardiograms |
|
| 10 |
Recruiting
|
Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones
| Condition: |
Healthy |
| Interventions: |
Drug: Saline; Drug: Glucagon; Drug: Placebo; Drug: Atenolol |
| Outcome Measures: |
Circulating acyl-ghrelin concentration after glucagon stimulation with and without beta-adrenergic blockade; Association between circulating acyl-ghrelin concentration and GH and cortisol after glucagon administration with and without beta-adrenergic blockade |
|
| 11 |
Recruiting
|
Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study
| Condition: |
Hypertension |
| Intervention: |
Drug: Lisinopril, Atenolol |
| Outcome Measure: |
One type of blood pressure medication will better treat individuals with certain genetic backgrounds. |
|
| 12 |
Recruiting
|
Comparison of Beta-blocker Versus Angiotensin Receptor Blocker for Suppression of Aneurysm Expansion in Patients With Small Abdominal Aortic Aneurysm
| Condition: |
Small Abdominal Aortic Aneurysm |
| Interventions: |
Drug: Beta-blocker-Atenolol 50mg, PO(peroral), Once daily; Drug: Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily |
| Outcome Measure: |
Annual aneurysm growth of abdominal aortic aneurysm |
|
| 13 |
Not yet recruiting
|
Single Pill to Avert Cardiovascular Events
| Condition: |
Cardiovascular Disease |
| Interventions: |
Drug: polipillV1; Drug: polipillV2; Drug: usual care |
| Outcome Measures: |
compliance with treatment; changed in blood pressure; changes in LDL-cholesterol levels; the main reason for non compliance with treatment; safety of poli pill measures by laboratorial tests; combined outcome |
|
| 14 |
Recruiting
|
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Cardiovascular Risk Assessment
| Conditions: |
Essential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease |
| Interventions: |
Drug: Any antihypertensive medication alone or in combination; Device: Ambulatory blood pressure monitoring |
| Outcome Measures: |
To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular and renal risk assessment.; To evaluate the influence of circadian time of treatment in BP control of hypertensive patients.; To evaluate the prevalence of an altered (non-dipper) BP profile in patients with resistant hypertension as a function of the circadian time of treatment.; To evaluate the influence of diabetes and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.; To evaluate the influence of age and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.; To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of white-coat hypertension.; To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of masked hypertension.; To evaluate, for all previous objectives, potential differences between men and women.; To evaluate the impact of changes in ambulatory BP in cardiovascular, cerebrovascular and renal risk assessment. |
|
| 15 |
Recruiting
|
Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF
| Condition: |
Atrial Fibrillation |
| Intervention: |
Other: Aggressive Blood Pressure control |
| Outcome Measures: |
Time to recurrent Atrial fibrillation; Recurrence of AF at one year |
|
| 16 |
Unknown †
|
Heart Rate Reduction in Heart Failure
| Condition: |
Heart Failure |
| Interventions: |
Drug: ivabradine; Drug: Carvedilol/Ivabradine; Drug: Carvedilol |
| Outcome Measures: |
Exercise tolerance assessed by 6 minute walking test; Quality of life |
|
| 17 |
Unknown †
|
Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study
| Conditions: |
Hypertension; Diabetes; Death From Cardiovascular Disease; Myocardial Infarction; Stroke |
| Intervention: |
|
| Outcome Measures: |
Number of participants who have died from cardiovascular disease and the number who have suffered a non-fatal myocardial infarction (MI) and/or non-fatal stroke since the end of the ASCOT study; Number of participants who have developed diabetes since the end of the ASCOT trial; Number of participants who have undergone coronary/peripheral re-vascularisation procedures since the end of the ASCOT trial; Number of participants who have required renal replacement therapy (dialysis or kidney transplant) since the end of the ASCOT trial; Number of participants who have experienced a transient ischaemic attack since the end of the ASCOT trial |
|
| 18 |
Recruiting
|
The International Polycap Study 3 (TIPS-3)
| Conditions: |
Cardiovascular Disease; Fractures; Cancers |
| Interventions: |
Drug: Polycap DS; Drug: enteric coated aspirin; Drug: cholecalciferol |
| Outcome Measures: |
Composite of major CVD (CV death, non-fatal stroke, non-fatal MI), plus heart failure, resuscitated cardiac arrest, or revascularization with evidence of ischemia in participants taking Polycap versus placebo; Composite of CV events (CV death, MI or stroke) and cancer in participants taking aspirin versus placebo; Risk of fractures in participants taking vitamin D versus placebo; Composite of CV death, non-fatal stroke, and nonfatal MI in participants taking Polycap versus placebo; Composite outcome of CV events and cancers after 10 years of follow up in participants taking aspirin versus placebo; Composite outcome of CV events, fractures and cancers, and the risk of the falls at 10 years of follow up in participants taking vitamin D versus placebo |
|
| 19 |
Recruiting
|
Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
| Conditions: |
Atrial Fibrillation; Arrhythmia |
| Interventions: |
Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy |
| Outcome Measures: |
LA catheter ablation is superior to rate or rhythm control drug therapy for decreasing the incidence of the composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest in patients warranting therapy for AF.; LA catheter ablation is superior to rate or rhythm control drug therapy for reducing total mortality; Total mortality or cardiovascular hospitalization; Cardiovascular death; Cardiovascular death or disabling stroke; Arrhythmic death or cardiac arrest; Heart failure death; Freedom from recurrent AF; Cardiovascular hospitalization; Medical costs, resource utilization, and cost effectiveness; Quality of Life; Composite adverse events; Left atrial size, morphology and function and its relationship to morbidity and mortality |
|
